Want to see JP:4571 full AI Analyst Report?
4571 Stock Chart & Stats
¥134.00
-¥1.00(-0.68%)
At close: 4:00 PM EST
¥134.00
-¥1.00(-0.68%)
Day’s Range― - ―
52-Week Range¥72.00 - ¥195.00
Previous CloseN/A
Volume236.30K
Average Volume (3M)790.59K
Market Cap
¥7.27B
Enterprise Value¥5.36B
Total Cash (Recent Filing)¥4.22B
Total Debt (Recent Filing)¥1.20B
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Nov 13, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.45
Shares Outstanding90,945,460
10 Day Avg. Volume1,420,270
30 Day Avg. Volume790,586
Financial Highlights & Ratios
PEG Ratio-1.32
Price to Book (P/B)3.10
Price to Sales (P/S)63.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Rebound And MarginsThe sharp revenue rebound, combined with consistently high gross margins, indicates that NanoCarrier can generate economically attractive sales when products or collaborations progress. If this recovery persists, it could provide a stronger base for funding development and narrowing losses over the next several quarters.
Proprietary DDS PlatformNanoCarrier’s proprietary drug-delivery technologies provide a differentiated platform for improving therapeutic compound delivery and efficacy. A reusable platform can support multiple candidates and therapeutic applications, creating longer-term partnering and product-development opportunities beyond any single program.
Moderate Leverage And Positive EquityModerate leverage and positive equity provide some balance-sheet cushion while the company develops its pipeline. This financial structure is less restrictive than a highly leveraged balance sheet, preserving some flexibility to pursue research, partnerships, and commercialization efforts despite current losses.
Bears Say
Persistent Deep LossesPersistent operating and net losses show that the business has not yet converted its technology and development activities into sustainable profitability. Even with improving results, the depth of losses leaves a substantial gap to break-even and makes future earnings dependent on continued execution and revenue growth.
Ongoing Cash BurnContinued operating cash consumption means the core business is not currently self-funding its activities. Negative cash generation can constrain investment in clinical development and commercialization, while dependence on external financing increases the company’s exposure if funding conditions or access to capital deteriorate.
Rising Debt And Shrinking EquityHigher debt alongside declining assets and equity signals weakening financial flexibility even though leverage remains moderate. If losses continue, the company may have fewer internal resources to absorb setbacks, and additional borrowing or funding could become increasingly important to sustain operations.
NanoCarrier Co., Ltd. News
4571 FAQ
What was NanoCarrier Co., Ltd.’s price range in the past 12 months?
NanoCarrier Co., Ltd. lowest stock price was ¥72.00 and its highest was ¥195.00 in the past 12 months.
What is NanoCarrier Co., Ltd.’s market cap?
NanoCarrier Co., Ltd.’s market cap is ¥7.27B.
When is NanoCarrier Co., Ltd.’s upcoming earnings report date?
NanoCarrier Co., Ltd.’s upcoming earnings report date is Nov 13, 2026 which is in 13 days.
How were NanoCarrier Co., Ltd.’s earnings last quarter?
NanoCarrier Co., Ltd. released its earnings results on Aug 07, 2026. The company reported -¥3.39 earnings per share for the quarter.
Is NanoCarrier Co., Ltd. overvalued?
According to Wall Street analysts NanoCarrier Co., Ltd.’s price is currently Overvalued.
Does NanoCarrier Co., Ltd. pay dividends?
NanoCarrier Co., Ltd. does not currently pay dividends.
What is NanoCarrier Co., Ltd.’s EPS estimate?
NanoCarrier Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does NanoCarrier Co., Ltd. have?
NanoCarrier Co., Ltd. has 90,945,460 shares outstanding.
What happened to NanoCarrier Co., Ltd.’s price movement after its last earnings report?
NanoCarrier Co., Ltd. reported an EPS of -¥3.39 in its last earnings report. Following the earnings report the stock price went up 1.01%.
Which hedge fund is a major shareholder of NanoCarrier Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4571
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
NanoCarrier Co., Ltd.
Nano Holdings, Inc. researches, develops, produces, and sells pharmaceuticals using micellar nanoparticles technology in Japan. The company’s pipeline products include RUNX1 (mRNA) for the treatment knee osteoarthritis and reduces pain; and NC-6100 PRDM14 (siRNA), which is in phase I clinical trials for the treatment of breast cancer. Its product pipeline also comprises TUG1 (ASO) for glioblastoma multiforme. In addition, it offers cosmetic raw material. The company was formerly known as NANO MRNA Co.,Ltd. and changed its name to Nano Holdings, Inc. in December 2025. Nano Holdings, Inc. was incorporated in 1996 and is headquartered in Minato, Japan.
Technical Analysis
AnGes
―
OncoTherapy Science
―
Chiome Bioscience Inc.
―
Oncolys BioPharma, Inc.
―
STELLA PHARMA CORPORATION
―